Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.…
Atea Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
Atea Pharmaceuticals (NASDAQ: AVIR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 55 employees.
The shares were at 3.960 USD on 20 November 2026, up 21.1% over 52 weeks. Its 52-week range is 2.870 USD to 6.450 USD: the price is 38.6% below the high and 38.0% above the low.
Its market capitalisation is 318.00M USD.
Atea Pharmaceuticals reports return on equity of -57.5% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 190.99M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 9.000 USD is 127.3% above the current price. The next earnings report is expected on 4 March 2027.